Paul Romness

Opinion author

Paul Romness is the chair, CEO and president of OS Therapies. He leads the company with over 25 years of experience in the biopharmaceutical industry, having served in multiple functions at Johnson & Johnson, Amgen, and Boehringer Ingelheim. He has been directly involved in the launch of nine major products spanning oncology, surgery, HIV, pulmonary disease, cardiovascular disease and diabetes, and has been a consistent advocate for addressing unmet medical need and getting treatments to patients.

Human hands created secure environment for small girl via home roof gesture. Childproofing, supervision, and teaching safety rules. Adoption and Adults taking care about kids. Vector illustration

Opinion

Why pediatric rare oncology outperforms in a volatile biotech market

Real progress happens where unmet medical need is greatest and patient impact can be clearly measured. Pediatric rare cancers exemplify these criteria and have therefore generated continued investment, even in a capital-constrained environment.

August 20, 2026

5 min read

Paul Romness